跳至主要内容
临床试验/NCT00635973
NCT00635973已完成3 期

Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.

AstraZeneca0 个研究点目标入组 100 人开始时间: 2000年2月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
AstraZeneca
入组人数
100
主要终点
Adverse Events

研究概览

简要总结

A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Received treatment in a previous Iressa clinical trial
  • Provided Informed Consent to participate in the trial
  • 30 days or less since completing the previous Iressa trial.

排除标准

  • Radiotherapy completed more than 14 days before starting treatment in this trial
  • Incomplete healing from prior surgery
  • Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs

结局指标

主要结局

Adverse Events

时间窗: Every 28 days

次要结局

  • Survival(Every 28 days)
  • Progression Free Survival(Every 28 days)

研究者

发起方
AstraZeneca
申办方类型
Industry

相似试验

Open-Label Extension of Other SZ1839 (Iressa) Trials | 临床试验